HOUSTON, July 29, 2004 (PRIMEZONE) -- Coastal Holdings, Inc. (Pink Sheets:CSJJ) today released a report on their Company prepared by Market Advisors Research. The complete, unedited text of that report is as follows.
COASTAL HOLDINGS,INC. (CSJJ.PK)
Stock Symbol- CSJJ.PK
Shares- 80,000,000
Float- 35,000,000
Recent price- $0.0035
Short term price- $0.4275
Web Site- www.coastalholdings.com
Investor Relations- 647-886-2703
NEWS FLASH: Coastal Holdings, Inc. signed a draft investment agreement to purchase a significant equity interest in BioSight Ltd - an Israel-based biotech company committed to redefine the way medicines are targeted and delivered. BioSight has already filed several worldwide patents to protect its S2DOT(tm) (Seek to Destroy Only Target) proprietary technology and has R&D collaborations with several academic and medical institutions. The Company is seeking funds in order to enable it to expand the development process and specifically to complete Phase II clinical trials. The market for drug delivery has been growing rapidly with a $40 billion forecast this year and is expected to grow to $70 billion by 2005, with BioSight Ltd. leading the way in the next generation of targeted therapies.
Investment Highlights
-- Coastal Holdings, Inc. is fueling its growth by an
aggressive acquisition strategy
-- The U.S. biotechnology industry employs over 191,000 people
and market-cap of these firms has exceeded $212 billion
-- Unique scientific and technological advances are being made
Coastal Holdings, Inc. was formed to become a viable holding company that will invest in leading edge and innovative technologies in the biotechnology sector. Companies that possess a competitive advantage in intellectual property and patents as well as licenses are what the company seeks to build on and thus creating shareholder value. Coastal Holdings is currently in merger and acquisition negotiations with various private technology companies and disclosure of these investments will be forthcoming upon completion of the due diligence process. More often than not the complexity of the problems we face today, whether these are technology or business related, requires solutions that combine techniques from various disciplines. Coastal Holdings, Inc. seeks to provide a private company that it invests in with tremendous exposure to the U.S. and international investment community as well.
The company is in the process of completing the acquisition of a stake in two revolutionary Israeli biotechnology firms that will make a shift in the paradigm of their respective fields. The advanced biotechnologies of both companies will be a giant step forward in benefiting and protecting mankind. The initial figures for this investment will be for a total of $5 million U.S. These acquisitions will be financially beneficial for shareholders of both companies.
Management
CEO Andrea Cortellazzi has been a successful entrepreneur for over 15 years. During this time, he has gained valuable contacts and knowledge in the high-growth biotechnology sector. Much of these contacts were with senior managers. Going forward in 2004, he has decided to pursue the acquisition of leading-edge biotechnology firms through his publicly traded company, Coastal Holdings Inc. These biotechnology firms are led by senior management with over 30 years of experience in this field.
Growth Opportunities
Coastal Holdings, Inc. and the biotechnology field as a whole has a distinct advantage in the market. The combination of technological advances, demographic increases in demand and immunity from the economic cycle make this sector extremely attractive over the next decade. It is imperative for the long-term success of biotechnology companies to have strong management in place as it often takes years to get a product approved. Led by CEO Mr. Cortellazzi, a stake in this company should prove to be quite profitable, as he possesses the vision and persistence that investors need on their side.
ANALYST -- Jeff Helleberg has over twenty years in the business and has been lead analyst for Market Advisors since 1985. Mr. Helleberg has been frequently quoted in a wide array of publications such as the Wall Street Journal, Barrons, Investors Business Daily, The Dick Davis Digest and many more. Jeff was the editor of the Marketarian Letter, a nationally syndicated stock market newsletter for over 14 years.
The information and opinions in this report were prepared by Market Advisors, Inc. which has at times served as financial relations counsel to the featured company and does receive fees for services including preparation of this report. For this report, $0 was paid, $2,000 was received for this fact sheet in May and other services to the Company. This is not an offer to buy or sell securities nor should this report be construed as investment advice. Information or statements are subject to numerous risks and uncertainties that cause such statements not to prove accurate. For a more detailed disclaimer, please contact MA.